• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

A broadly neutralizing human monoclonal antibody is effective against H7N9.

August 7, 2015 | PNAS
Kannan Tharakaraman et al.

A broadly neutralizing human monoclonal antibody is effective against H7N9.

Kannan Tharakaraman, Vidya Subramanian, Karthik Viswanathan, Susan Sloan, Hui-Ling Yen, Dale L. Barnard, Y. H. Connie Leung, Kristy J. Szretter, Tyree J. Koch, James C. Delaney, Gregory J. Babcock, Gerald N. Wogan, Ram Sasisekharan, and Zachary Shriver

>READ

© 2023 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design